{"id":480329,"date":"2026-06-03T04:13:08","date_gmt":"2026-06-03T04:13:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/480329\/"},"modified":"2026-06-03T04:13:08","modified_gmt":"2026-06-03T04:13:08","slug":"new-york-valves-2026-to-unveil-late-breaking-research-in-structural-heart-disease","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/480329\/","title":{"rendered":"New York Valves 2026 To Unveil Late-Breaking Research in Structural Heart Disease"},"content":{"rendered":"

Newswise \u2014 NEW YORK \u2013 June 2, 2026 \u2013 The Cardiovascular Research Foundation\u00ae (CRF\u00ae) announced the highly anticipated lineup of late-breaking research to be presented at New York Valves: The Structural Heart SummitTM<\/a>. The premier educational meeting for the structural heart community will take place June 24-26, 2026, at the Jacob K. Javits Convention Center, North in New York, NY.<\/p>\n

This year\u2019s program will feature 22 late-breaking clinical science and 8 late-breaking innovation<\/a> presentations that are poised to transform the treatment of structural heart disease. The research will reveal the latest breakthroughs in transcatheter aortic valve replacement (TAVR) and introduce next-generation innovations for mitral and tricuspid valve therapies. These findings are expected to immediately impact clinical practice, helping to refine patient selection, optimize techniques, and define the standard of care for new and emerging treatments.<\/p>\n

Now in its third year, New York Valves is the world\u2019s foremost educational forum for interventionalists, surgeons, and clinical cardiologists dedicated to the field of structural heart disease.<\/p>\n

Wednesday, June 24, 2026<\/p>\n

Late-Breaking Clinical Science: TAVR Session I<\/p>\n

10:15 AM \u2014 11:45 AM EDT<\/p>\n

\u00a0<\/p>\n

7-Year Valve Durability in the PARTNER 3 Trial<\/p>\n

Philippe Pibarot<\/p>\n

\u00a0<\/p>\n

Seven-Year TAVR Outcomes in Low-Risk Patients treated with Balloon-Expandable Valves in the United States<\/p>\n

Sreekanth Vemulapalli<\/p>\n

\u00a0<\/p>\n

Outcomes of TAVR with the Evolut Platform: Results from the VA-CART Program<\/p>\n

Neel Butala<\/p>\n

\u00a0<\/p>\n

8-Year Durability and Reintervention with the Evolut Valve: Single-Center Results<\/p>\n

Sachin S. Goel<\/p>\n

\u00a0<\/p>\n

6-Year Outcomes from the Evolut TAVR Low-Risk Bicuspid Study<\/p>\n

Basel Ramlawi<\/p>\n

\u00a0<\/p>\n

TAVR for Asymptomatic Severe AS: Updated Results from the EARLY-TAVR trial<\/p>\n

Philippe Genereux<\/p>\n

\u00a0<\/p>\n

Late-Breaking Clinical Science: Tricuspid<\/p>\n

1:45\u00a0PM\u00a0\u2014 2:45\u00a0PM EDT<\/p>\n

\u00a0<\/p>\n

Transcatheter Tricuspid Valve Replacmement after Failed T-TEER: The REDEMPTION registry<\/p>\n

Prasham Dave<\/p>\n

\u00a0<\/p>\n

Treatment Pathways and Outcomes in TRISCEND-Ineligible Patients: A Single-Center Study<\/p>\n

Ashtyn N. Williams<\/p>\n

\u00a0<\/p>\n

Thirty-day Outcomes After T-TEER with the TriClip System: Early Experience from the TVT Registry<\/p>\n

Wayne Batchelor<\/p>\n

\u00a0<\/p>\n

Valve Thrombosis after TTVR: The TRIPLACE Registry<\/p>\n

Julio Echarte Morales<\/p>\n

\u00a0<\/p>\n

Thursday, June 25, 2026<\/p>\n

Late-Breaking Clinical Science: Mitral<\/p>\n

10:15 AM \u2014 11:45 AM EDT<\/p>\n

\u00a0<\/p>\n

One-Year Outcomes of M3 TMVR in Patients with Mitral Annular Calcification: The ENCIRCLE-MAC<\/p>\n

Mayra Guerrero<\/p>\n

\u00a0<\/p>\n

LAMPOON Trends and Outcomes: Insights from the STS\/ACC TVT Registry<\/p>\n

Jaffar M. Khan<\/p>\n

\u00a0<\/p>\n

One-Year Outcomes of PASCAL M-TEER: Real-World Evidence from the TVT Registry<\/p>\n

Azeem Latib<\/p>\n

\u00a0<\/p>\n

Repeat M-TEER in the TVT Registry: Temporal Trends, Predictors, and Outcomes<\/p>\n

John Thomas Saxon<\/p>\n

\u00a0<\/p>\n

Real-World Evaluation of MitraClip vs. PASCAL for M-TEER<\/p>\n

Pier Pasquale Leone<\/p>\n

\u00a0<\/p>\n

M-TEERr for Patients With a Small Mitral Valve Orifice Area: The REPAIR Study<\/p>\n

Philipp von Stein<\/p>\n

\u00a0<\/p>\n

Late-Breaking Innovation I<\/p>\n

1:45\u00a0PM\u00a0\u2014 2:45\u00a0PM EDT<\/p>\n

\u00a0<\/p>\n

AI-Enabled ECG analysis for Detection and Prediction of Structural Heart Disease<\/p>\n

Hak Seung Lee<\/p>\n

\u00a0<\/p>\n

EVolution Of heart vaLVe teams and the patient Experience (EVOLVE): A Multicenter, Mixed Methods Study of TAVR Programs Across the United States<\/p>\n

Dhaval Kolte<\/p>\n

\u00a0<\/p>\n

Real-World Outcomes of the Shortcut Device for Leaflet Modification Prior to ViV TAVR<\/p>\n

Raj R. Makkar<\/p>\n

\u00a0<\/p>\n

BASILICA Trends and Outcomes: Insights from the STS\/ACC TVT Registry<\/p>\n

Jaffar M. Khan<\/p>\n

\u00a0<\/p>\n

Friday, June 26, 2026<\/p>\n

Late-Breaking Clinical Science: TAVR Session II<\/p>\n

10:15 AM \u2014 11:45 AM EDT<\/p>\n

\u00a0<\/p>\n

Baseline Clinical and Echocardiographic Characteristics among Moderate AS Patients Enrolled in the PROGRESS Trial<\/p>\n

Raj R. Makkar<\/p>\n

\u00a0<\/p>\n

Measuring Quality in the Evaluation, Surveillance, and Treatment of Aortic Stenosis: First Large-Scale Report from the AHA Target AS Initiative<\/p>\n

Brian R. Lindman<\/p>\n

\u00a0<\/p>\n

A Prospective Multicenter Study of an EHR-Facilitated Valve Care Pathway for Severe Aortic Stenosis: The DETECT AS II Study<\/p>\n

Sammy Elmariah<\/p>\n

\u00a0<\/p>\n

Real-World Outcomes of TAVR with the NAVITOR valve for Patients with Small Aortic Annuli: Results from the STS\/ACC Registry<\/p>\n

Raviteja Reddy Guddeti<\/p>\n

\u00a0<\/p>\n

A Randomized Trial Comparing Femoral or Radial Secondary Access in TAVR<\/p>\n

Antony Walton<\/p>\n

\u00a0<\/p>\n

New Permanent Pacemaker Implantation After TAVR for Pure Aortic Regurgitation: Results from the ALIGN-AR Study<\/p>\n

James M. McCabe<\/p>\n

\u00a0<\/p>\n

Late-Breaking Innovation II<\/p>\n

1:45\u00a0PM\u00a0\u2014 2:45\u00a0PM EDT<\/p>\n

\u00a0<\/p>\n

Pulsed Field Ablation of the LAA Prior to LAA Closure: A Novel Approach to Reduce Peri-Device Leak<\/p>\n

Vivek Y. Reddy<\/p>\n

\u00a0<\/p>\n

M-TEER vs. Valve-In-Ring in Patients with Failed Surgical Mitral Valve Repair: Insights from the REDO-MR Registry<\/p>\n

Guido Ascione<\/p>\n

\u00a0<\/p>\n

Six-Month Outcomes of Mitral Valve Lithotripsy using the SMARTCRACK Balloon for Mitral Stenosis with Severe Mitral Annular or Valvular Calcification: The SMART-MAC trial<\/p>\n

Kent Chak-yu So<\/p>\n

\u00a0<\/p>\n

TAVR with the JenaValve Trilogy System in Patients with Continous-Flow LVADS: The JENA-VAD NOW Registry<\/p>\n

Ravi Ramana<\/p>\n

\u00a0<\/p>\n

In addition to late-breaking research, New York Valves will feature:<\/p>\n

Live cases showcasing groundbreaking procedures performed by world-renowned operators from prestigious medical institutions180+ scientific abstracts220+ challenging casesReturning for a second year, the LAAC Summit<\/a> is a high-impact program featuring real-world case reviews and live cases with critical insights from leading experts.\u00a0And much more!<\/p>\n

\u00a0<\/p>\n

HOW TO REGISTER:<\/p>\n

Media may apply for press registration by emailing jromero@crf.org<\/a>.<\/p>\n

\u00a0<\/p>\n

About CRF\u00ae<\/p>\n

The Cardiovascular Research Foundation\u00ae (CRF\u00ae) is a global leader in interventional cardiovascular medicine, driving innovation, spearheading groundbreaking research, and transforming education in the field. Through its relentless pursuit of excellence, CRF not only accelerates medical breakthroughs but also equips healthcare professionals with the tools and knowledge necessary to enhance survival rates and elevate the quality of life for millions worldwide. CRF\u2019s centers of excellence include the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD\u00ae, and Structural Heart: The Journal of the Heart Team.<\/p>\n

\u00a0<\/p>\n

For more information, visit www.crf.org<\/a>.<\/p>\n

\u00a0<\/p>\n

###<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Newswise \u2014 NEW YORK \u2013 June 2, 2026 \u2013 The Cardiovascular Research Foundation\u00ae (CRF\u00ae) announced the highly anticipated…\n","protected":false},"author":2,"featured_media":384823,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[206988,6776,206989,8845,396,3274,61,60,1378,76957,3066,80],"class_list":["post-480329","post","type-post","status-publish","format-standard","has-post-thumbnail","category-technology","tag-cardiovascular-diseaseheart-diseaseinterventional-cardiologystructural-heart-disease","tag-cardiovascular-health","tag-cardiovascular-research-foundation-crf","tag-clinical-trials","tag-healthcare","tag-heart-disease","tag-ie","tag-ireland","tag-newswise","tag-patient-safety","tag-surgery","tag-technology"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/480329","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=480329"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/480329\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/384823"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=480329"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=480329"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=480329"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}